Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

October 01, 1992; Volume 42,Issue 4
  • You have access
    Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus.
    J D Kursar, D L Nelson, D B Wainscott, M L Cohen and M Baez
    Molecular Pharmacology October 1992, 42 (4) 549-557;
  • You have access
    Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.
    R F Kletzien, L A Foellmi, P K Harris, B M Wyse and S D Clarke
    Molecular Pharmacology October 1992, 42 (4) 558-562;
  • You have access
    Cloning and expression of a high affinity taurine transporter from rat brain.
    K E Smith, L A Borden, C H Wang, P R Hartig, T A Branchek and R L Weinshank
    Molecular Pharmacology October 1992, 42 (4) 563-569;
  • You have access
    Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle.
    H J Duff, J Offord, J West and W A Catterall
    Molecular Pharmacology October 1992, 42 (4) 570-574;
  • You have access
    kappa-Opioid inhibition of [3H]dopamine release from rat ventral mesencephalic dissociated cell cultures.
    J A Smith, S E Loughlin and F M Leslie
    Molecular Pharmacology October 1992, 42 (4) 575-583;
  • You have access
    Modulation of platelet-derived growth factor B mRNA abundance in macrophages by colchicine and dibutyryl-cAMP.
    A Wangoo, A R Haynes, S P Sutcliffe, M Sorooshian and R J Shaw
    Molecular Pharmacology October 1992, 42 (4) 584-589;
  • You have access
    Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
    P Fossé, B René, M Charra, C Paoletti and J M Saucier
    Molecular Pharmacology October 1992, 42 (4) 590-595;
  • You have access
    Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers.
    D G Rhodes, R Newton, R Butler and L Herbette
    Molecular Pharmacology October 1992, 42 (4) 596-602;
  • You have access
    In vitro transformation of the human Ah receptor and its binding to a dioxin response element.
    P A Harper, J V Giannone, A B Okey and M S Denison
    Molecular Pharmacology October 1992, 42 (4) 603-612;
  • You have access
    Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1).
    K W Bock, H Gschaidmeier, A Seidel, S Baird and B Burchell
    Molecular Pharmacology October 1992, 42 (4) 613-618;
  • You have access
    [3H]noscapine binding sites in brain: relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems.
    R J Mourey, T M Dawson, R K Barrow, A E Enna and S H Snyder
    Molecular Pharmacology October 1992, 42 (4) 619-626;
  • You have access
    Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors.
    M S Choudhary, S Craigo and B L Roth
    Molecular Pharmacology October 1992, 42 (4) 627-633;
  • You have access
    Functional properties of the rat and human beta 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells.
    S B Liggett
    Molecular Pharmacology October 1992, 42 (4) 634-637;
  • You have access
    Two allosteric modulators interact at a common site on cardiac muscarinic receptors.
    J Ellis and M Seidenberg
    Molecular Pharmacology October 1992, 42 (4) 638-641;
  • You have access
    Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
    M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
    Molecular Pharmacology October 1992, 42 (4) 642-648;
  • You have access
    Influence of age on the beta 1- and beta 2-adrenergic receptors in rat liver.
    A Van Ermen, E Van de Velde, P Vanscheeuwijck and N Fraeyman
    Molecular Pharmacology October 1992, 42 (4) 649-655;
  • You have access
    Protein kinase C activation increases the rate and magnitude of agonist-induced delta-opioid receptor down-regulation in NG108-15 cells.
    S Gucker and J M Bidlack
    Molecular Pharmacology October 1992, 42 (4) 656-665;
  • You have access
    Characterization of the effects of a new Ca2+ channel activator, FPL 64176, in GH3 cells.
    D L Kunze and D Rampe
    Molecular Pharmacology October 1992, 42 (4) 666-670;
  • You have access
    Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells.
    M A Varney, P P Godfrey, A H Drummond and S P Watson
    Molecular Pharmacology October 1992, 42 (4) 671-678;
  • You have access
    Effect of extracellular pH on the potency of N-methyl-D-aspartic acid receptor competitive antagonists.
    M Benveniste and M L Mayer
    Molecular Pharmacology October 1992, 42 (4) 679-686;
  • You have access
    Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development.
    J Barredo and R G Moran
    Molecular Pharmacology October 1992, 42 (4) 687-694;
  • You have access
    Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
    Y Kumagai, L Y Lin, R M Philpot, H Yamada, K Oguri, H Yoshimura and A K Cho
    Molecular Pharmacology October 1992, 42 (4) 695-702;
  • You have access
    Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury.
    R J Rothman, A Serroni and J L Farber
    Molecular Pharmacology October 1992, 42 (4) 703-710;
  • You have access
    Hypersensitivity to acetaldehyde-protein adducts.
    Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
    Molecular Pharmacology October 1992, 42 (4) 711-717;
  • You have access
    Correlations between the rate constant of singlet oxygen quenching by imidazole derivatives and anti-inflammatory activity in rats.
    R V Bensasson, J Frederiksen, M Rougée, D Lexa and N Harrit
    Molecular Pharmacology October 1992, 42 (4) 718-722;
  • You have access
    In vivo evidence of hydroxyl radical formation after acute copper and ascorbic acid intake: electron spin resonance spin-trapping investigation.
    M B Kadiiska, P M Hanna, L Hernandez and R P Mason
    Molecular Pharmacology October 1992, 42 (4) 723-729;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 42, Issue 4
1 Oct 1992
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics